BL-8040: Phase II started

BioLineRx began an open-label, U.S. Phase II trial to evaluate subcutaneous BL-8040 in about 24 donor/recipient pairs. Donors will receive BL-8040 followed by leukapheresis on day 1 to reach >=5x10 6 ...